
CSL
CMXHF | OTC
$127.68
+$0.18 (+0.14%)
At close: Oct 5, 2026, 4:00 PM ET
CSL Company Profile
Company profile explainedCompany Profile
CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company's activities are organized into two primary divisions: CSL Behring and Seqirus. CSL Behring specializes in plasma-derived therapies, delivering essential plasma products and recombinant treatments designed to manage a range of serious conditions such as immunodeficiencies, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. Beyond its therapeutic offerings, this division actively pursues research in both plasma and non-plasma-based treatments, and also generates revenue through licensing and royalties from its intellectual property commercialization. Meanwhile, Seqirus focuses on the manufacturing and distribution of non-plasma biotherapeutics, alongside the development of innovative influenza vaccines and related products. Established in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Key Executives
| Name | Position |
|---|---|
| Gordon Naylor DipCompSc | MD, Chief Executive Officer & Executive Director |
| Amy Van Buren | Chief People Officer |
| Ken Lim | Chief Financial Officer |
| Deirdre BeVard | Senior Vice President of Research & Development Strategic Operations |
| Gregory Boss | Executive VP of Legal & Group General Counsel |
| Herve Gisserot | Executive VP of Business Development & Enterprise Alliance Management |
| Kate Sophie Priestman | Chief Corporate & External Affairs Officer |
| Mark Dehring | Head of Investor Relations |
| Mark Hill | Chief Digital Information Officer & Executive Vice President |
| Mary Oates | Executive VP & COO |
| Michelle Rees | Head of Investor Relations |
| Stephen Marlow | Executive VP & GM of CSL Plasma |
| William Mezzanotte | Chief Medical Officer, Executive Vice President and Head of Research & Development |
CSL

| Country | Australia |
| IPO Date | Nov 18, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29,000 |
| CEO | Gordon Naylor DipCompSc |
Contact Details
655 Elizabeth Street Melbourne,
VIC 3000 Australia
Stock Details
| Ticker Symbol | CMXHF |
| Exchange | OTC |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001274152 |
| CUSIP Number | n/a |
| ISIN Number | AU000000CSL8 |
| SIC Code |
Recent News
- 3 months ago / cnbc.comTrump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Add to Watchlist
Select watchlists to add or remove CMXHF